Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics Statistics
Share Statistics
Xilio Therapeutics has 51.77M shares outstanding. The number of shares has increased by 40.26% in one year.
| Shares Outstanding | 51.77M |
| Shares Change (YoY) | 40.26% |
| Shares Change (QoQ) | 17.78% |
| Owned by Institutions (%) | 40.74% |
| Shares Floating | 15.84M |
| Failed to Deliver (FTD) Shares | 3.83K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 644.53K, so 1.24% of the outstanding shares have been sold short.
| Short Interest | 644.53K |
| Short % of Shares Out | 1.24% |
| Short % of Float | 1.46% |
| Short Ratio (days to cover) | 2.5 |
Valuation Ratios
The PE ratio is -0.88 and the forward PE ratio is -1.21. Xilio Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.88 |
| Forward PE | -1.21 |
| PS Ratio | 8.06 |
| Forward PS | 0.6 |
| PB Ratio | 2.9 |
| P/FCF Ratio | -2.78 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Xilio Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.46.
| Current Ratio | 2.21 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $99.13K |
| Profits Per Employee | $-910.02K |
| Employee Count | 64 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -24.53% in the last 52 weeks. The beta is -0.22, so Xilio Therapeutics's price volatility has been lower than the market average.
| Beta | -0.22 |
| 52-Week Price Change | -24.53% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 0.9 |
| Relative Strength Index (RSI) | 54.65 |
| Average Volume (20 Days) | 3.81M |
Income Statement
In the last 12 months, Xilio Therapeutics had revenue of 6.34M and earned -58.24M in profits. Earnings per share was -1.09.
| Revenue | 6.34M |
| Gross Profit | 6.34M |
| Operating Income | -60.58M |
| Net Income | -58.24M |
| EBITDA | -58M |
| EBIT | -59.65M |
| Earnings Per Share (EPS) | -1.09 |
Balance Sheet
The company has 55.29M in cash and 8.14M in debt, giving a net cash position of 47.15M.
| Cash & Cash Equivalents | 55.29M |
| Total Debt | 8.14M |
| Net Cash | 47.15M |
| Retained Earnings | -383.75M |
| Total Assets | 71.08M |
| Working Capital | 32.97M |
Cash Flow
In the last 12 months, operating cash flow was -18.38M and capital expenditures -36K, giving a free cash flow of -18.41M.
| Operating Cash Flow | -18.38M |
| Capital Expenditures | -36K |
| Free Cash Flow | -18.41M |
| FCF Per Share | -0.34 |
Margins
Gross margin is 100%, with operating and profit margins of -954.95% and -918.05%.
| Gross Margin | 100% |
| Operating Margin | -954.95% |
| Pretax Margin | -918.05% |
| Profit Margin | -918.05% |
| EBITDA Margin | -914.27% |
| EBIT Margin | -954.95% |
| FCF Margin | -290.26% |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for XLO is $4, which is 400% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 400% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -9.21 |
| Piotroski F-Score | 4 |